TARGETING AKT AND DNA-PK AS A THERAPEUTIC STRATEGY IN PLATINUM RESISTANT HIGH-GRADE SEROUS OVARIAN CANCER

1Natasha Rinne, 1Shengnan Yuan, 1Christina Fotopoulou, 2Hani Gabra, 1Paula Cunnea.
1Imperial College London; Division of Cancer, Department of Surgery and Cancer; 2Bergenbio, Magdalen Centre; Robert Robinson Avenue, The Oxford Science Park.

Introduction/Background Malignant sex cord stroma cell tumours (SCST) account for less than eight percent of ovarian malignancies. The Arbeitsgemeinschaft fuer Gynaekologische Onkologie (AGO) has established a clinicopathological (Current Ovarian geRm cell and SExor cord stromal Tumour Treatment strategies, CORSETT) database for a better documentation and understanding of this rare disease. Here, we present the first clinicopathological descriptive analysis for patients with independently confirmed SCST from the CORSETT database.

Methodology 20 German centres entered mixed retro- and prospective data of SCST patients with tumour specimens available treated between 2000 to 2014 into the CORSETT database. An independent CORSETT pathology reference panel checked the primary histological diagnosis.

We conducted a descriptive analysis of the treatment strategies and created Kaplan-Meier curves and cox regression analyses for the survival analysis.

Results The reference pathology panel diagnosed 143 patients with granulosa cell (GCT, FIGO stage I= 120, 87.0%) and 14 patients with Sertoli-Leydig cell (SLCT, FIGO stage I = 11, 91.7%) tumours (others = 5). The median age of patients with GCT was 57.6 years (SLCT: 47.2 years). 87 of GCT (61.7%) and eight SLCT (57.1%) patients were treated with laparoscopy and the tumour ruptured intraoperatively in 22% (SLCT: 7.7%) of the cases. 57 GCT (45%) and eight SLCT (57%) patients received fertility-sparing surgery. 19 of GCT (15%) and two SLCT (15.4%) patients received adjuvant chemotherapy. 59 of GCT (45%) and two of SLCT (14.3%) patients experienced a disease recurrence. The median progression-free survival (PFS) for all SCST patients was 80.4 months, (overall survival not reached). Advanced FIGO stage was associated with decreased PFS (p < 0.05).

Adjuvant chemotherapy had no statistically significant beneficial effect on PFS (all regimens p > 0.05).

Conclusion In this analysis, almost every fourth SCST patient treated surgically experienced an intraoperative cyst rupture that had however no impact on disease recurrence. One in five SCST patient received adjuvant chemotherapy that had no PFS improvement.

Disclosures

TREATING STRATEGIES AND SURVIVAL OF WOMEN WITH MALIGNANT OVARIAN GERM CELL TUMOURS – AN ANALYSIS OF THE AGO-CORSETT DATABASE

1Annette Hasenburg, 1Helmut Plett, 2Philipp Harter, 3Stefan Karmass, 4Jaqueline Keul, 5Eva Roser, 6Bastian Czogalla, 8Michaela Bosser, 9Theresa Link, 10Maximilian Klar, 1Dept Gynecology and Obstetrics; University Center Mainz; Klinik und Poliklinik für Geburtshilfe und Frauenheilkunde; 2Klinikum Essen; Gynaecology; 3Klinikum Essen; Gynaecology; 4Universitätsklinikum Tübingen; Universitätsfrauenklinik; 5University Hospital Tuebingen; 6Charite Berlin; 7UMU Munich; Obstetrics and Gynaecology; 8Universitätsklinikum Freiburg; University of Freiburg; Obstetrics and Gynaecology; 9Uniklinik Dresden; Gynaekologie und Geburtshilfe; Obstetrics and Gynaecology; 10University of Freiburg.

Introduction/Background High-grade serous ovarian cancer (HGSOC) is the most lethal form of gynaecological malignancy. Despite initial sensitivity to platinum chemotherapy, the majority of patients develop resistance to treatment and eventually die. Current treatment options for platinum-resistant patients are limited.

The role of the PI3K/AKT/mTOR pathway has been described in chemo-resistant HGSOC, in particular through activation of AKT by DNA-PK in response to platinum treatment. As increasing numbers of AKT and DNA-PK inhibitors advance to clinical trials, determining mechanism of action and efficacy is crucial.

This project aims to evaluate inhibition of AKT or DNA-PK as a therapeutic strategy to target platinum resistance in HGSOC, and identify proteomic signatures confirming mechanism of action and target inhibition.

Methodology A panel of seven AKT and DNA-PK inhibitors were tested in combination with cisplatin chemotherapy in immortalised HGSOC cell lines and primary tumour cells cultured from HGSOC tumour/ascites samples. Clonogenic assays were performed to establish effect of inhibitor treatment in combination with cisplatin chemotherapy on the ability of cells to form colonies. Isobologram assays were performed to establish synergy/antagonism between inhibitors and cisplatin chemotherapy. Proteomic Reverse Phase Protein Array (RPPA) was performed to determine the mechanism of action of inhibitors, and results were confirmed with immunoblotting.

Results Treatment with AKT or DNA-PK inhibitors in combination with cisplatin led to significantly enhanced apoptotic responses in immortalised platinum-resistant HGSOC cell lines (n=5), and in primary cells derived from ascites or tumour (n=4, p<0.01, p<0.05), compared to cisplatin treatment alone. In platinum-resistant HGSOC cell lines, fewer cell colonies were observed with increasing concentrations of AKT or DNA-PK inhibitors in combination with cisplatin (n=3) in comparison with cisplatin alone. Varying synergistic effects were observed across the panel of inhibitors when combined with cisplatin; Uprosertib (AKT inhibitor) in particular displayed strong synergy with cisplatin (Loewe analysis). Proteomic analysis of inhibitor treatment in HGSOC platinum-resistant cells demonstrated the mechanism of action of Uprosertib in targeting the PI3K/AKT pathway.

Conclusion In platinum-resistant HGSOC cells, AKT or DNA-PK inhibition functioned synergistically with cisplatin and reduced cell growth and proliferation. In both immortalised and primary HGSOC cell lines tested, AKT or DNA-PK inhibition significantly enhanced the apoptotic response to cisplatin demonstrating the efficacy of AKT or DNA-PK as potential therapeutic targets in chemoresistant HGSOC. By improving patient response to treatment, AKT and DNA-PK inhibitors could expand the therapeutic options for patients with platinum-resistant HGSOC, improving overall survival.

Disclosures CF: advisory boards and honoraria from Roche, Tesaro, Sequana, Olympus, Astra Zeneca. Other authors have no conflict of interest.
PATIENT-REPORTED OUTCOMES (PROS) IN PATIENTS (PTS) RECEIVING NIRAPARIB IN THE PRIMA/ENGOT-OV26/GOG-3012 TRIAL

1Johanna Mäenpää, 2Bhavana Pothuri, 3Silyen Han, 4Dana Chase, 5David Bender, 6Philippe Follana, 7Emeline Bacque, 8LI Yong, 8Antonio González-Martin, 9Bradley J Monk.
1Tampere University; 2Gynecologic Oncology Group (GOG); Perlmutter Cancer Center, Nu Langone Health; Department of Obstetrics/Gynecology; 3University Hospitals Leuven; Department of Obstetrics and Gynecology; 4Arizona Oncology (US Oncology Network), University of Arizona College of Medicine; 5University of Iowa; Department of Obstetrics and Gynecology; 6Geneva Centre Antoine Lacassagne; 7GiselasmithklineGrupo Español de Investigación En Cáncer de Ovario (Giselasmithkline); 8GiselasmithklineGrupo Español de Investigación En Cáncer de Ovario (Giselasmithkline); 9University of Arizona College of Medicine

10.1136/ijgc-2020-ESGO.114

Background Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor that is approved for use in heavily pretreated pts and as maintenance treatment of pts with newly diagnosed or recurrent ovarian cancer following a response to platinum-based chemotherapy (CT). Here we report PROs in pts receiving niraparib and placebo (PBO) in the PRIMA/ENGOT-OV26/GOG-3012 trial.

Methods This double-blind, PBO-controlled, phase 3 study randomised 733 pts with newly diagnosed advanced ovarian, primary peritoneal, or fallopian tube cancer with a complete or partial response (CR or PR) to first-line (1L) platinum-based CT. Pts received niraparib or PBO once daily for 36 months or until disease progression. The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review. PROs, a secondary endpoint, were collected every 8 weeks for 56 weeks, then every 12 weeks thereafter while treatment was ongoing. Once a pt discontinued treatment, PRO evaluations were performed at the time of treatment discontinuation and then at 4, 8, 12, and 24 weeks (+1 week for each time point) after the end of treatment, regardless of the status of subsequent treatment. The validated PRO instruments utilised were FOSI, EQ-5D-5L, EORTC-QLQ-C30, and EORTC-QLQ-OV28.

Results Compliance rates were high for all of the PRO instruments used in the study. PRO analysis of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 did not indicate a difference in health-related quality of life scores of pts treated with niraparib vs placebo. Mean scores between niraparib and placebo arms were similar at each time point. Overall, the health utility index showed a slight improvement trend in pts who received niraparib vs placebo.

Conclusion Consistent with PRO results in the NOVA study, pts receiving niraparib in the PRIMA trial did not experience a decrease in quality of life compared with those receiving placebo.

Disclosures Sponsor: GlaxoSmithKline, Waltham, MA, USA
NCT number: NCT02655016
Encore statement: This data is presented on behalf of the original authors with their permission. Presented at the European Society for Medical Oncology (ESMO) Annual Meeting, September 19–21, 2020, Virtual.

Dr. Mäenpää reports Honoraria from Tesaro, AstraZeneca, Clovis, Roche, MSD and OrionPharma
Dr. Pothuri reports grants, personal fees and non-financial support from GSK; Advisory Board fees from AstraZeneca and Clovis Oncology
Dr. Chase reports speakers’ bureau fees from GSK.
Dr. González-Martín reports personal fees and non-financial support from AstraZeneca; Grant and personal fees from GSK, Clovis Oncology, Roche Holding AG, Merck & Co., Inc., Genmab, INMUNOGEN, Pharma Mar S.A., and Oncivent AS.

Dr. Monk reports consulting and advisory role at Merck, GSK, Roche/Genentech, AstraZeneca, Advaxis, Celgene, AstraZeneca, Merck, Genentech, Pfizer, Mateon Therapeutics, Precision Oncology, Perthera, Abbvie, Myriad Pharmaceuticals, Incyte, VBL Therapeutics, Takeda, Samumed, Oncomed, OncoSec, Chemoid, Geistlich Pharma, Eisai and Chemocare; Speakers’ bureau at Roche/Genentech, AstraZeneca, Janssen, Clovis Oncology and GSK; Honoraria from Merck, GSK, Roche/Genentech, AstraZeneca, Advaxis, Immunogen, NuCana BioMed, Clovis Oncology, Pfizer, Mateon Therapeutics, Precision Oncology, Pethera, Abbvie, Myriad Pharmaceuticals, Incyte, Janssen, Amgen, Genmab, Samumed, Takeda, VBL Therapeutics, Puma Biotechnology, Immunomedics, Conjupro Biotherapeutics, Agenus, OncoQuest, Chemoid, Geistlich Pharma, Eisai and Chemocare; and Research funding from Novartis, Amgen, Roche, Genentech, AstraZeneca, Advaxis, Celgene, AstraZeneca, Merck, Genentech, Pfizer, Mateon Therapeutics, Precision Oncology, Perthera, Abbvie, Myriad Pharmaceuticals, Incyte, VBL Therapeutics, Takeda, Samumed, Oncomed, OncoSec, Chemoid, Geistlich Pharma, Eisai and Chemocare; and Research funding from Novartis, Amgen, Roche, Genentech, AstraZeneca, Advaxis, Celgene, AstraZeneca, Merck, Genentech, Pfizer, Mateon Therapeutics, Precision Oncology, Pethera, Abbvie, Myriad Pharmaceuticals, Incyte, Janssen, Amgen, Genmab, Samumed, Takeda, VBL Therapeutics, Puma Biotechnology, Immunomedics, Conjupro Biotherapeutics, Agenus, OncoQuest, Chemoid, Geistlich Pharma, Eisai and Chemocare; and Research funding from Novartis, Amgen, Roche, Genentech, AstraZeneca, Advaxis, Celgene, AstraZeneca, Merck, Genentech, Pfizer, Mateon Therapeutics, Precision Oncology, Pethera, Abbvie, Myriad Pharmaceuticals, Incyte, Janssen, Amgen, Genmab, Samumed, Takeda, VBL Therapeutics, Puma Biotechnology, Immunomedics, Conjupro Biotherapeutics, Agenus, OncoQuest, Chemoid, Geistlich Pharma, Eisai and Chemocare; and Research funding from Novartis, Amgen, Roche, Genentech, AstraZeneca, Advaxis, Celgene, AstraZeneca, Merck, Genentech, Pfizer, Mateon Therapeutics, Precision Oncology, Pethera, Abbvie, Myriad Pharmaceuticals, Incyte, Janssen, Amgen, Genmab, Samumed, Takeda, VBL Therapeutics, Puma Biotechnology, Immunomedics, Conjupro Biotherapeutics, Agenus, OncoQuest, Chemoid, Geistlich Pharma, Eisai and Chemocare; and Research funding from Novartis, Amgen, Roche, Genentech, AstraZeneca, Advaxis, Celgene, AstraZeneca, Merck, Genentech, Pfizer, Mateon Therapeutics, Precision Oncology, Pethera, Abbvie, Myriad Pharmaceuticals, Incyte, Janssen, Amgen, Genmab, Samumed, Takeda, VBL Therapeutics, Puma Biotechnology, Immunomedics, Conjupro Biotherapeutics, Agenus, OncoQuest, Chemoid, Geistlich Pharma, Eisai and Chemocare; and Research funding from Novartis, Amgen, Roche, Genentech, AstraZeneca, Advaxis, Celgene, AstraZeneca, Merck, Genentech, Pfizer, Mateon Therapeutics, Precision Oncology, Pethera, Abbvie, Myriad Pharmaceuticals, Incyte, Janssen, Amgen, Genmab, Samumed, Takeda, VBL Therapeutics, Puma Biotechnology, Immunomedics, Conjupro Biotherapeutics, Agenus, OncoQuest, Chemoid, Geistlich Pharma, Eisai and Chemocare; and Research funding from Novartis, Amgen, Roche, Genentech, AstraZeneca, Advaxis, Celgene, AstraZeneca, Merck, Genentech, Pfizer, Mateon Therapeutics, Precision Oncology, Pethera, Abbvie, Myriad Pharmaceuticals, Incyte, Janssen, Amgen, Genmab, Samumed, Takeda, VBL Therapeutics, Puma Biotechnology, Immunomedics, Conjupro Biotherapeutics, Agenus, OncoQuest, Chemoid, Geistlich Pharma, Eisai and Chemocare; and Research funding from Novartis, Amgen, Roche, Genentech, AstraZeneca, Advaxis, Celgene, AstraZeneca, Merck, Genentech, Pfizer, Mateon Therapeutics, Precision Oncology, Pethera, Abbvie, Myriad Pharmaceuticals, Incyte, Janssen, Amgen, Genmab, Samumed, Takeda, VBL Therapeutics, Puma Biotechnology, Immunomedics, Conjupro Biotherapeutics, Agenus, OncoQuest, Chemoid, Geistlich Pharma, Eisai and Chemocare; and Research funding from Novartis, Amgen, Roche, Genentech, AstraZeneca, Advaxis, Celgene, AstraZeneca, Merck, Genentech, Pfizer, Mateon Therapeutics, Precision Oncology, Pethera, Abbvie, Myriad Pharmaceuticals, Incyte, Janssen, Amgen, Genmab, Samumed, Takeda, VBL Therapeutics, Puma Biotechnology, Immunomedics, Conjupro Biotherapeutics, Agenus, OncoQuest, Chemoid, Geistlich Pharma, Eisai and Chemocare; and Research funding from Novartis, Amgen, Roche, Genentech, AstraZeneca, Advaxis, Celgene, AstraZeneca, Merck, Genentech, Pfizer, Mateon Therapeutics, Precision Oncology, Pethera, Abbvie, Myriad Pharmaceuticals, Incyte, Janssen, Amgen, Genmab, Samumed, Takeda, VBL Therapeutics, Puma Biotechnology, Immunomedics, Conjupro Biotherapeutics, Agenus, OncoQuest, Chemoid, Geistlich Pharma, Eisai and Chemocare; and Research funding from Novartis, Amgen, Roche, Genentech, AstraZeneca, Advaxis, Celgene, AstraZeneca, Merck, Genentech, Pfizer, Mateon Therapeutics, Precision Oncology, Pethera, Abbvie, Myriad Pharmaceutical...